Latest market price
6.20
-0.19-2.97%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -1.91 | Insider Own | — | Shs Outstand | 107.22M | Perf Week | 4.73% |
| Market Cap | 664.79M | Forward P/E | — | EPS next Y | -1.69 | Insider Trans | -0.01% | Shs Float | 87.48M | Perf Month | -11.17% |
| Enterprise Value | 304.80M | PEG | — | EPS next Q | -0.37 | Short Float | 14.06% | Perf Quarter | -22.69% | ||
| Income | -208.00M | P/S | — | EPS this Y | — | Short Ratio | 10.81 | Perf Half Y | -13.04% | ||
| Sales | 0.00 | P/B | 1.78 | EPS next Y | — | ROA | -49.24% | Short Interest | 12.30M | Perf YTD | 9.93% |
| Book/sh | 3.49 | P/C | 1.76 | EPS next 5Y | — | ROE | -72.28% | 52W High | 11.45 -45.85% | Perf Year | 12.93% |
| Cash/sh | 3.53 | P/FCF | — | EPS past 3/5Y | — | ROIC | -53.81% | 52W Low | 3.79 63.59% | Perf 3Y | 202.44% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 7.06% 6.77% | Perf 5Y | -79.64% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.45 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 13.82 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 42.36 | Recom | 2.22 |
| Dividend Gr. 3/5Y | — | Current Ratio | 13.82 | EPS Q/Q | 9.52% | SMA20 | -1.35% | Beta | 2.59 | Target Price | 20.50 |
| Payout | 0.00% | Debt/Eq | 0.05 | Sales Q/Q | — | SMA50 | -20.65% | Rel Volume | 0.74 | Prev Close | 6.39 |
| Employees | 121 | LT Debt/Eq | 0.05 | Earnings | Nov 02 | SMA200 | -19.06% | Avg Volume | 1.18M | Price | 6.20 |
| IPO Date | Jan 26, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 17.81% — | Net Debt/EBITDA | — | Volume | 873,117 | Change | -2.97% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-16-26 | Initiated | RBC Capital | Outperform | $18 |
| Sep-14-26 | Reiterated | Loop Capital Markets | ||
| Aug-27-26 | Reiterated | Cantor Fitzgerald | Overweight | $16 |
| Aug-21-26 | Reiterated | Truist Securities | Buy | $20 |
| May-13-26 | Reiterated | Wedbush | Outperform | $16 |
| May-13-26 | Reiterated | Piper Sandler | Overweight | $20 → $18 |
| Dec-04-25 | Initiated | Needham | Buy | $16 |
| Nov-04-25 | Reiterated | Barclays | Overweight | $18 → $9.00 |
| Jul-21-25 | Reiterated | Cantor Fitzgerald | $16 | |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
Latest News· Times ET
Oct-26-26
Oct-26-2608:00AM
05:11AM
04:03AM
Oct-20-26
Oct-20-2608:00AM
Oct-15-26
Oct-15-2601:28PM
Oct-09-26
Oct-01-26
Oct-01-2604:05PM
Sep-25-26
Sep-25-2606:49AM
Sep-16-26
Sep-16-2604:14AM
Sep-10-26
Sep-10-2601:47PM
Sep-02-26
Aug-27-26
Aug-21-26
Aug-21-2609:30AM
Aug-10-26
Aug-10-2604:02AM
Aug-06-26
Company
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 2 | 2 | 3 | — | — | — | — | — | |
| Gross Profit | 0 | -2 | -2 | -3 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 44 | 39 | 33 | 28 | — | — | — | — | — | |
| Research and Development | 167 | 140 | 96 | 77 | — | — | — | — | — | |
| Other Operating Expense | 0 | -1 | -2 | -3 | — | — | — | — | — | |
| Operating Income | -211 | -179 | -130 | -104 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 6 | 5 | 5 | 8 | — | — | — | — | — | |
| Net Income Before Taxes | -208 | -174 | -125 | -96 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -208 | -174 | -125 | -96 | — | — | — | — | — | |
| Net Income From Continuing Operations | -208 | -174 | -125 | -96 | — | — | — | — | — | |
| Net Income | -208 | -174 | -125 | -96 | — | — | — | — | — | |
| EPS (Recurring) | -1.91 | -1.99 | -3.06 | -4.83 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.91 | -1.99 | -3.06 | -4.83 | — | — | — | — | — | |
| EPS (Diluted) | -1.91 | -1.99 | -3.06 | -4.83 | — | — | — | — | — | |
| EBITDA | -204 | -173 | -122 | -93 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 110 | 88 | 41 | 20 | — | — | — | — | — | |
| Market Capitalization | 682 | 496 | 164 | 123 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Brooks Gabriel | Chief Medical Officer | Oct 19 '26 | Sale | 5.62 | 4,374 | 24,582 | 97,241 | Oct 20 |
| Brooks Gabriel | Chief Medical Officer | Oct 18 '26 | Option Exercise | 0.00 | 9,750 | 0 | 101,615 | Oct 20 |
| SMITH IAN F | Director | Oct 02 '26 | Option Exercise | 0.00 | 3,440 | 0 | 141,585 | Oct 06 |
| SMITH IAN F | Director | Jul 02 '26 | Option Exercise | 0.00 | 3,440 | 0 | 138,145 | Jul 07 |
| SMITH IAN F | Director | Apr 02 '26 | Option Exercise | 0.00 | 3,441 | 0 | 134,705 | Apr 02 |
| Herzich Paul | Chief Technology Officer | Feb 18 '26 | Sale | 5.82 | 3,616 | 21,057 | 72,638 | Feb 18 |
| Cumbo Alexander | President and CEO | Feb 18 '26 | Sale | 5.82 | 16,644 | 96,923 | 235,405 | Feb 18 |
| Howton David T | Chief Operating Officer | Feb 18 '26 | Sale | 5.82 | 7,469 | 43,494 | 105,077 | Feb 18 |
| Ganot Ilan | Director | Feb 18 '26 | Sale | 5.82 | 2,658 | 15,478 | 27,474 | Feb 18 |
| Brooks Gabriel | Chief Medical Officer | Feb 18 '26 | Sale | 5.82 | 0 | 0 | 89,466 | Feb 18 |
| Hanrahan Jessie | Chief Regulatory Officer | Feb 18 '26 | Sale | 5.82 | 4,134 | 24,074 | 74,318 | Feb 18 |
| Tan Kevin | CFO & Treasurer | Feb 18 '26 | Sale | 5.82 | 5,404 | 31,469 | 99,422 | Feb 18 |
| Cumbo Alexander | President and CEO | Feb 13 '26 | Option Exercise | 0.00 | 30,031 | 0 | 252,049 | Feb 18 |
| Hanrahan Jessie | Chief Regulatory Officer | Feb 13 '26 | Option Exercise | 0.00 | 8,125 | 0 | 78,452 | Feb 18 |
| Ganot Ilan | Director | Feb 13 '26 | Option Exercise | 0.00 | 4,861 | 0 | 30,132 | Feb 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.